Vaxxas makes David Hoey its first CEO
This article was originally published in Scrip
Executive Summary
Vaxxas, a privately-held biotech company focused on commercialising its vaccine platform Nanopatch, has appointed David Hoey its first CEO. Mr Hoey most recently served as a board member and vice-president of business development for PathoGenetix.